MobiHealth News March 3, 2022
Also: Rupa Health raised $20 million for its lab test platform and CancerIQ scooped up $14 million in Series B funding.
Drug discovery startup ArrePath announced Thursday it has raised $20 million in a seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures.
Other participants in the round include Viva BioInnovator, Arimed Capital, PTX Capital and Nor’easter Ventures. The company, which focuses on developing new types of anti-infective drugs to best antimicrobial resistance, plans to use the investment to support its machine learning-based drug discovery platform.
ArrePath also appointed Dr. Lloyd Payne as president and CEO. Payne most recently served as executive vice president, head of anti-infectives, at German drug discovery company Evotec.